JP2024105526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105526A5 JP2024105526A5 JP2024078396A JP2024078396A JP2024105526A5 JP 2024105526 A5 JP2024105526 A5 JP 2024105526A5 JP 2024078396 A JP2024078396 A JP 2024078396A JP 2024078396 A JP2024078396 A JP 2024078396A JP 2024105526 A5 JP2024105526 A5 JP 2024105526A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- administered
- dose
- adenovirus
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1807932.7A GB201807932D0 (en) | 2018-05-16 | 2018-05-16 | Compositions and methods for inducing an immune response |
| GB1807932.7 | 2018-05-16 | ||
| JP2020561892A JP2021528367A (ja) | 2018-05-16 | 2019-05-16 | 免疫応答を誘導するための組成物 |
| PCT/EP2019/062694 WO2019219851A1 (en) | 2018-05-16 | 2019-05-16 | Compositions for inducing an immune response |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561892A Division JP2021528367A (ja) | 2018-05-16 | 2019-05-16 | 免疫応答を誘導するための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105526A JP2024105526A (ja) | 2024-08-06 |
| JP2024105526A5 true JP2024105526A5 (https=) | 2024-09-13 |
Family
ID=62623405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561892A Withdrawn JP2021528367A (ja) | 2018-05-16 | 2019-05-16 | 免疫応答を誘導するための組成物 |
| JP2024078396A Pending JP2024105526A (ja) | 2018-05-16 | 2024-05-14 | 免疫応答を誘導するための組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561892A Withdrawn JP2021528367A (ja) | 2018-05-16 | 2019-05-16 | 免疫応答を誘導するための組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12246038B2 (https=) |
| EP (1) | EP3793581A1 (https=) |
| JP (2) | JP2021528367A (https=) |
| KR (1) | KR102810080B1 (https=) |
| CN (2) | CN112088012A (https=) |
| AU (1) | AU2019270424A1 (https=) |
| CA (1) | CA3097951A1 (https=) |
| GB (1) | GB201807932D0 (https=) |
| MX (1) | MX2020012150A (https=) |
| SG (1) | SG11202010862VA (https=) |
| WO (1) | WO2019219851A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4444347A1 (en) * | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0203419D0 (en) * | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
| GB201006405D0 (en) * | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| EP2912183B1 (en) * | 2012-10-28 | 2020-05-06 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
-
2018
- 2018-05-16 GB GBGB1807932.7A patent/GB201807932D0/en not_active Ceased
-
2019
- 2019-05-16 US US17/055,056 patent/US12246038B2/en active Active
- 2019-05-16 JP JP2020561892A patent/JP2021528367A/ja not_active Withdrawn
- 2019-05-16 CN CN201980030633.8A patent/CN112088012A/zh active Pending
- 2019-05-16 CN CN202411963750.9A patent/CN119770632A/zh active Pending
- 2019-05-16 AU AU2019270424A patent/AU2019270424A1/en not_active Abandoned
- 2019-05-16 CA CA3097951A patent/CA3097951A1/en active Pending
- 2019-05-16 WO PCT/EP2019/062694 patent/WO2019219851A1/en not_active Ceased
- 2019-05-16 KR KR1020207036057A patent/KR102810080B1/ko active Active
- 2019-05-16 SG SG11202010862VA patent/SG11202010862VA/en unknown
- 2019-05-16 EP EP19734251.2A patent/EP3793581A1/en active Pending
- 2019-05-16 MX MX2020012150A patent/MX2020012150A/es unknown
-
2024
- 2024-05-14 JP JP2024078396A patent/JP2024105526A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105526A5 (https=) | ||
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| CN103772508B (zh) | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 | |
| CA2282300A1 (en) | Recombinant pox virus for immunization against muc1 tumor-associated antigen | |
| CN116732101A (zh) | 用于治疗hbv的手段和方法 | |
| Mennuni et al. | Efficient induction of T‐cell responses to carcinoembryonic antigen by a heterologous prime‐boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA | |
| JP2024105526A (ja) | 免疫応答を誘導するための組成物 | |
| JP2022516770A5 (https=) | ||
| JP2021528367A5 (https=) | ||
| Restifo et al. | Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer | |
| Haq et al. | Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen | |
| CA2527640A1 (en) | Tumor antigens for prevention and/or treatment of cancer | |
| JP2025084850A5 (https=) | ||
| JP2010523138A5 (https=) | ||
| Harrop et al. | Viral vectors for cancer immunotherapy | |
| WO2006061643A1 (en) | Method for vaccinating usign a prime-boost regime and hsv as a vector | |
| CA3133971A1 (en) | Sequential heterologous boost oncolytic viral mmunotherapy | |
| Rittich et al. | Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2 | |
| WO2024218165A1 (en) | Hpv viral vector vaccine | |
| TWI259206B (en) | A DNA vaccine containing a tumor associated gene and a cytokine gene and the method producing thereof | |
| JP2024521364A5 (https=) | ||
| AU775973B2 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response | |
| Palmowski et al. | Heterologous prime-boost vaccination in tumor immunotherapy | |
| CN112399855A (zh) | 作为佐剂的溶瘤病毒 | |
| Chamberlain et al. | THE USE OF RECOMBINANT POXVIRUSES AS A PARADIGM FOR THE DEVELOPMENT OF ANTI-CANCER VACCINES |